Jeff Jackson is an accomplished professional in the field of translational medicine, currently serving as Group Vice President at Incyte since October 2023, prior to which Jackson held the position of Vice President of Translational Sciences at the same company from July 2019 to March 2023. With extensive experience at Bristol-Myers Squibb from April 2009 to June 2019, Jackson operated as Development Lead in Hematology and also led early asset development in Oncology. Prior roles include Group Director of Oncology Biomarkers at GlaxoSmithKline and various positions at Smithkline Beecham Pharmaceuticals. Jackson's educational background includes a BS, MS, and PhD in Molecular Genetics and Biology from the University of Rochester.
This person is not in any teams
This person is not in any offices